NDA 207500 · Astellas
Cresemba
Isavuconazonium Sulfate · Oral
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Mar 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Mar 6, 2015
Approved uses
2
Original approval plus efficacy supplements
Registered trials
11
2 Phase 3, 0 recruiting
FAERS reports
3,844
2,685 serious, 770 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 25, 2025.
CRESEMBA ® is an azole antifungal indicated for the treatment of: Invasive aspergillosis ( 1.1 ) and Invasive mucormycosis ( 1.2 ) as follows: • CRESEMBA for injection : adults and pediatric patients 1 year of age and older • CRESEMBA capsules : adults and pediatric patients 6 years of age and older who weigh 16 kilograms (kg) and greater 1.1 Invasive Aspergillosis CRESEMBA ® is indicated for the treatment of invasive aspergillosis as follows: CRESEMBA for injection : adults and pediatric patients 1 year of age and older [see Clinical Studies ( 14.1 ) and Clinical Pharmacology ( 12.4 )] CRESEMBA capsules : adults and pediatric patients 6 years of age and older who weigh 16 kilograms (kg) and greater [see Dosage and Administration ( 2.3 ) Clinical Studies ( 14.1 ) and Clinical Pharmacology ( 12.4 )] 1.2 Invasive Mucormycosis CRESEMBA is indicated for the treatment of invasive mucormycosis as follows: CRESEMBA for injection : adults and pediatric patients 1 year of age and older [see Clinical Studies ( 14.1 ) and Clinical Pharmacology ( 12.3 , 12.4 )] CRESEMBA capsules : adults and pediatric patients 6 years of age and older who weigh 16 kg and greater [see Dosage and Administration ( 2.3 )], Clinical Studies ( 14.1 ) and Clinical Pharmacology ( 12.3 , 12.4 )] 1.3 Usage Specimens for fungal culture and other relevant laboratory studies (including histopathology) to isolate and identify causative organism(s) should be obtained prior to initiating antifungal therapy. Therapy may be instituted before the results of the cultures and other laboratory studies are known. However, once these results become available, antifungal therapy should be adjusted accordingly.
Mechanism: Isavuconazonium sulfate is the prodrug of isavuconazole, an azole antifungal [see Microbiology ( 12.4 )] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 8, 2023 Supplement 15 · Efficacy · priority review OrphanLabelLetter
- Mar 6, 2015 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelReviewSummary Review
2 products under this application
- CRESEMBA · ISAVUCONAZONIUM SULFATE 74.5MG · CAPSULE, ORAL · Prescription
- CRESEMBA · ISAVUCONAZONIUM SULFATE 186MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Isavuconazonium" as an intervention, any sponsor and status, largest first.
- Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep MycosisPivotal-lookingCompleted
Asahi Kasei Therapeutics CorporationIndustry
NCT03471988 · 103 participants · Start Apr 16, 2018 · Primary completion Apr 21, 2021
Drug: AK1820; Voriconazole · For: Deep Mycosis
Sites: Nagakute, Japan; Nagoya, Japan; Seto, Japan · 33 sites in all
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT03149055 · 99 participants · Start May 4, 2017 · Primary completion Aug 20, 2019
Drug: Isavuconazole · For: Hematologic Malignancy; Myeloproliferative Disorder
Sites: New York, New York
PfizerPfizer (PFE)
NCT05630976 · 70 participants · Start Feb 7, 2023 · Primary completion Apr 11, 2025
Drug: Isavuconazole · For: Invasive Fungal Disease
Sites: Hefei, China; Guangzhou, China; Jieyang, China · 14 sites in all
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT03241550 · 49 participants · Start Oct 2, 2017 · Primary completion Jul 5, 2019
Drug: isavuconazonium sulfate - intravenous; isavuconazonium sulfate - oral · For: Hematological Malignancy
Sites: Long Beach, California; Los Angeles, California; Orange, California · 16 sites in all
- Study of Monzosertib In Patients With R/R AML Or High-Risk Myelodysplastic SyndromeNot yet recruiting
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT07780565 · 42 participants (planned) · Start Jan 1, 2027 · Primary completion Aug 30, 2029
Drug: Monzosertib; Posaconazole and 1 more · For: Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome
Sites: Houston, Texas
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT03816176 · 31 participants · Start Aug 22, 2019 · Primary completion Dec 14, 2022
Drug: Isavuconazonium sulfate; Isavuconazonium sulfate · For: Invasive Mucormycosis; Invasive Aspergillosis
Sites: Los Angeles, California; Orange, California; Washington D.C., District of Columbia · 10 sites in all
Acerta Pharma BVAstraZeneca (AZN)
NCT05140096 · 30 participants · Start Jan 3, 2020 · Primary completion Apr 15, 2020
Drug: Acalabrutinib; Fluconazole and 1 more · For: Healthy Volunteers
Sites: Tempe, Arizona
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT04096157 · 17 participants · Start Sep 24, 2019 · Primary completion Jan 16, 2020
Drug: Isavuconazonium sulfate IV; Isavuconazonium sulfate capsules · For: Healthy Subjects
Sites: Baltimore, Maryland
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use1,094
- death344
- nausea190
- drug ineffective173
- febrile neutropenia151
- pyrexia150
- pneumonia142
- condition aggravated136
- fatigue127
- diarrhoea114
- dyspnoea109
- product use in unapproved indication106
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 57 |
| 2016 | 250 |
| 2017 | 575 |
| 2018 | 238 |
| 2019 | 269 |
| 2020 | 269 |
| 2021 | 208 |
| 2022 | 250 |
| 2023 | 253 |
| 2024 | 364 |
| 2025 | 520 |
| 2026 | 591 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cresemba* (Isavuconazonium Sulfate)
2024 spending
$123M
Beneficiaries
4,665
19,216 claims
Per beneficiary
$26,374
$107.62 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $55,590,672 |
| 2021 | $59,881,233 |
| 2022 | $72,575,256 |
| 2023 | $95,684,253 |
| 2024 | $123,034,269 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
Maertens JA, Raad II, Marr KA, et al. · Lancet 2016 · Clinical Trial, Phase III, Comparative Study
- Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.
Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. · Lancet Infect Dis 2016 · Clinical Trial
- Safety, outcomes, and pharmacokinetics of isavuconazole as a treatment for invasive fungal diseases in pediatric patients: a non-comparative phase 2 trial.
Segers H, Deville JG, Muller WJ, et al. · Antimicrob Agents Chemother 2024 · Clinical Trial, Phase II, Multicenter Study
- Pharmacokinetics and Bioequivalence of Isavuconazole Administered as Isavuconazonium Sulfate Intravenous Solution via Nasogastric Tube or Orally in Healthy Subjects.
Desai A, Helmick M, Heo N, et al. · Antimicrob Agents Chemother 2021 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Isavuconazonium Sulfate in Healthy Adult Japanese Subjects.
Shirae S, Ose A, Kumagai Y · Clin Pharmacol Drug Dev 2022 · Randomized Controlled Trial
- Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response.
Kovanda LL, Kolamunnage-Dona R, Neely M, et al. · Clin Infect Dis 2017 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Astellas
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.